Logo image of LLY

ELI LILLY & CO (LLY) Stock Fundamental Analysis

NYSE:LLY - US5324571083 - Common Stock

727.21 USD
-15.7 (-2.11%)
Last: 9/5/2025, 8:27:19 PM
726.5 USD
-0.71 (-0.1%)
After Hours: 9/5/2025, 8:27:19 PM
Fundamental Rating

6

Overall LLY gets a fundamental rating of 6 out of 10. We evaluated LLY against 195 industry peers in the Pharmaceuticals industry. While LLY belongs to the best of the industry regarding profitability, there are concerns on its financial health. LLY is not priced too expensively while it is growing strongly. Keep and eye on this one! Finally LLY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

LLY had positive earnings in the past year.
In the past year LLY had a positive cash flow from operations.
LLY had positive earnings in each of the past 5 years.
LLY had a positive operating cash flow in each of the past 5 years.
LLY Yearly Net Income VS EBIT VS OCF VS FCFLLY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

LLY has a better Return On Assets (13.67%) than 94.36% of its industry peers.
With an excellent Return On Equity value of 75.52%, LLY belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
LLY has a Return On Invested Capital of 29.63%. This is amongst the best in the industry. LLY outperforms 97.95% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for LLY is significantly above the industry average of 15.28%.
The last Return On Invested Capital (29.63%) for LLY is above the 3 year average (21.71%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.67%
ROE 75.52%
ROIC 29.63%
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
LLY Yearly ROA, ROE, ROICLLY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

LLY's Profit Margin of 25.91% is amongst the best of the industry. LLY outperforms 95.90% of its industry peers.
LLY's Profit Margin has declined in the last couple of years.
LLY's Operating Margin of 42.13% is amongst the best of the industry. LLY outperforms 97.95% of its industry peers.
LLY's Operating Margin has improved in the last couple of years.
LLY's Gross Margin of 82.64% is amongst the best of the industry. LLY outperforms 87.69% of its industry peers.
In the last couple of years the Gross Margin of LLY has remained more or less at the same level.
Industry RankSector Rank
OM 42.13%
PM (TTM) 25.91%
GM 82.64%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
LLY Yearly Profit, Operating, Gross MarginsLLY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so LLY is creating value.
LLY has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, LLY has less shares outstanding
LLY has a worse debt/assets ratio than last year.
LLY Yearly Shares OutstandingLLY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
LLY Yearly Total Debt VS Total AssetsLLY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

An Altman-Z score of 6.74 indicates that LLY is not in any danger for bankruptcy at the moment.
LLY has a better Altman-Z score (6.74) than 83.08% of its industry peers.
A Debt/Equity ratio of 1.87 is on the high side and indicates that LLY has dependencies on debt financing.
With a Debt to Equity ratio value of 1.87, LLY is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Altman-Z 6.74
ROIC/WACC3
WACC9.86%
LLY Yearly LT Debt VS Equity VS FCFLLY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B

2.3 Liquidity

LLY has a Current Ratio of 1.28. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
LLY has a Current ratio of 1.28. This is in the lower half of the industry: LLY underperforms 74.36% of its industry peers.
A Quick Ratio of 1.00 indicates that LLY may have some problems paying its short term obligations.
LLY's Quick ratio of 1.00 is on the low side compared to the rest of the industry. LLY is outperformed by 73.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1
LLY Yearly Current Assets VS Current LiabilitesLLY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.67% over the past year.
Measured over the past years, LLY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.57% on average per year.
Looking at the last year, LLY shows a very strong growth in Revenue. The Revenue has grown by 36.83%.
LLY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.08% yearly.
EPS 1Y (TTM)77.67%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%60.97%
Revenue 1Y (TTM)36.83%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%37.64%

3.2 Future

The Earnings Per Share is expected to grow by 30.54% on average over the next years. This is a very strong growth
LLY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.75% yearly.
EPS Next Y76.85%
EPS Next 2Y53.25%
EPS Next 3Y42.28%
EPS Next 5Y30.54%
Revenue Next Year36.89%
Revenue Next 2Y27.13%
Revenue Next 3Y23.54%
Revenue Next 5Y17.75%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
LLY Yearly Revenue VS EstimatesLLY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
LLY Yearly EPS VS EstimatesLLY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

LLY is valuated quite expensively with a Price/Earnings ratio of 45.03.
79.49% of the companies in the same industry are more expensive than LLY, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of LLY to the average of the S&P500 Index (27.06), we can say LLY is valued expensively.
A Price/Forward Earnings ratio of 23.82 indicates a rather expensive valuation of LLY.
LLY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LLY is cheaper than 72.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.69. LLY is around the same levels.
Industry RankSector Rank
PE 45.03
Fwd PE 23.82
LLY Price Earnings VS Forward Price EarningsLLY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

LLY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LLY is cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.38
LLY Per share dataLLY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

LLY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LLY has an outstanding profitability rating, which may justify a higher PE ratio.
LLY's earnings are expected to grow with 42.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)2.72
EPS Next 2Y53.25%
EPS Next 3Y42.28%

More info and screens

7

5. Dividend

5.1 Amount

With a yearly dividend of 0.82%, LLY is not a good candidate for dividend investing.
LLY's Dividend Yield is rather good when compared to the industry average which is at 5.73. LLY pays more dividend than 89.23% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, LLY's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.82%

5.2 History

On average, the dividend of LLY grows each year by 15.60%, which is quite nice.
LLY has been paying a dividend for at least 10 years, so it has a reliable track record.
LLY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)15.6%
Div Incr Years10
Div Non Decr Years34
LLY Yearly Dividends per shareLLY Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4 5

5.3 Sustainability

36.46% of the earnings are spent on dividend by LLY. This is a low number and sustainable payout ratio.
The dividend of LLY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP36.46%
EPS Next 2Y53.25%
EPS Next 3Y42.28%
LLY Yearly Income VS Free CF VS DividendLLY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B 6B 8B 10B
LLY Dividend Payout.LLY Dividend Payout, showing the Payout Ratio.LLY Dividend Payout.PayoutRetained Earnings

More info and screens

ELI LILLY & CO

NYSE:LLY (9/5/2025, 8:27:19 PM)

After market: 726.5 -0.71 (-0.1%)

727.21

-15.7 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners84.01%
Inst Owner Change-8.75%
Ins Owners0.16%
Ins Owner Change-0.52%
Market Cap688.28B
Analysts81.21
Price Target910.18 (25.16%)
Short Float %0.92%
Short Ratio1.82
Dividend
Industry RankSector Rank
Dividend Yield 0.82%
Yearly Dividend4.93
Dividend Growth(5Y)15.6%
DP36.46%
Div Incr Years10
Div Non Decr Years34
Ex-Date08-15 2025-08-15 (1.5)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.94%
Min EPS beat(2)9.38%
Max EPS beat(2)14.51%
EPS beat(4)3
Avg EPS beat(4)2.5%
Min EPS beat(4)-20.34%
Max EPS beat(4)14.51%
EPS beat(8)7
Avg EPS beat(8)31.01%
EPS beat(12)10
Avg EPS beat(12)22.08%
EPS beat(16)12
Avg EPS beat(16)15.86%
Revenue beat(2)1
Avg Revenue beat(2)2.11%
Min Revenue beat(2)-0.5%
Max Revenue beat(2)4.72%
Revenue beat(4)1
Avg Revenue beat(4)-0.87%
Min Revenue beat(4)-6.46%
Max Revenue beat(4)4.72%
Revenue beat(8)4
Avg Revenue beat(8)1.92%
Revenue beat(12)6
Avg Revenue beat(12)1.89%
Revenue beat(16)9
Avg Revenue beat(16)1.54%
PT rev (1m)-7.82%
PT rev (3m)-10.2%
EPS NQ rev (1m)3.53%
EPS NQ rev (3m)2.97%
EPS NY rev (1m)5.23%
EPS NY rev (3m)5.27%
Revenue NQ rev (1m)3.32%
Revenue NQ rev (3m)4.87%
Revenue NY rev (1m)2.9%
Revenue NY rev (3m)3.96%
Valuation
Industry RankSector Rank
PE 45.03
Fwd PE 23.82
P/S 12.92
P/FCF N/A
P/OCF 62.92
P/B 37.67
P/tB 104.38
EV/EBITDA 30.38
EPS(TTM)16.15
EY2.22%
EPS(NY)30.53
Fwd EY4.2%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)11.56
OCFY1.59%
SpS56.27
BVpS19.31
TBVpS6.97
PEG (NY)0.59
PEG (5Y)2.72
Profitability
Industry RankSector Rank
ROA 13.67%
ROE 75.52%
ROCE 36.25%
ROIC 29.63%
ROICexc 31.43%
ROICexgc 39.29%
OM 42.13%
PM (TTM) 25.91%
GM 82.64%
FCFM N/A
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
ROICexc(3y)23.23%
ROICexc(5y)21.74%
ROICexgc(3y)32.89%
ROICexgc(5y)32.31%
ROCE(3y)29.19%
ROCE(5y)26%
ROICexcg growth 3Y1.59%
ROICexcg growth 5Y4.02%
ROICexc growth 3Y9.55%
ROICexc growth 5Y8.81%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Debt/EBITDA 1.4
Cap/Depr 580.51%
Cap/Sales 20.63%
Interest Coverage 250
Cash Conversion 44.95%
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1
Altman-Z 6.74
F-Score6
WACC9.86%
ROIC/WACC3
Cap/Depr(3y)374.28%
Cap/Depr(5y)279.43%
Cap/Sales(3y)16.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.67%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%60.97%
EPS Next Y76.85%
EPS Next 2Y53.25%
EPS Next 3Y42.28%
EPS Next 5Y30.54%
Revenue 1Y (TTM)36.83%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%37.64%
Revenue Next Year36.89%
Revenue Next 2Y27.13%
Revenue Next 3Y23.54%
Revenue Next 5Y17.75%
EBIT growth 1Y67.12%
EBIT growth 3Y31.18%
EBIT growth 5Y24.1%
EBIT Next Year84.34%
EBIT Next 3Y42.93%
EBIT Next 5Y30.03%
FCF growth 1Y-101.56%
FCF growth 3Y-57.48%
FCF growth 5Y-34.68%
OCF growth 1Y75.24%
OCF growth 3Y6.69%
OCF growth 5Y12.76%